Skip to main content

Advertisement

Advertisement

World

FDA okays Regeneron COVID-19 antibody as preventive in high-risk settings

The US Food and Drug Administration has expanded the emergency use authorisation of Regeneron Pharmaceuticals's COVID-19 antibody cocktail, enabling its use as a preventive treatment for the illness in certain people.

FDA okays Regeneron COVID-19 antibody as preventive in high-risk settings

FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermid/File Photo

WASHINGTON: The US Food and Drug Administration has expanded the emergency use authorisation of Regeneron Pharmaceuticals's COVID-19 antibody cocktail, enabling its use as a preventive treatment for the illness in certain people.

The company said the authorisation enables the therapy to be used in people exposed to an infected individual, or who are at high risk of exposure to an infected individual in settings such as nursing homes or prisons.

The combo therapy, REGEN-COV, was authorised in November for emergency use to treat people with mild-to-moderate COVID-19 in the United States.

REGEN-COV, a combination of casirivimab and imdevimab, protected household contacts from exposure to SARS-CoV-2, with 72 per cent protection against symptomatic infections in the first week, and 93 per cent after that, according to trial data released by the company in April.

Regeneron said the expanded authorisation will help address the needs of immunocompromised people, including those taking immunosuppressive medicines, whose bodies may not mount an adequate response to COVID-19 vaccination.

BOOKMARK THIS: Our comprehensive coverage of the COVID-19 pandemic and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram

Source: Reuters

Advertisement

Also worth reading

Advertisement